CONCLUSION: The CASQ-first pathway may reduce assessment costs and redirect a substantial proportion of referrals away from a direct full ADHD assessment, but the present validation study is not adequately powered to support a definitive economic conclusion. Because the economic result rests on a sensitivity estimate derived from only six confirmed ADHD cases, the projected per-referral and national savings are illustrative planning estimates and not established savings. The economic estimates…
